383 related articles for article (PubMed ID: 11991685)
21. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
[TBL] [Abstract][Full Text] [Related]
22. COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
Saha D; Pyo H; Choy H
Am J Clin Oncol; 2003 Aug; 26(4):S70-4. PubMed ID: 12902860
[TBL] [Abstract][Full Text] [Related]
23. [Analgesic effects of cyclooxygenase 2 inhibitors].
Jayr C
Bull Cancer; 2004 May; 91 Spec No():S125-31. PubMed ID: 15239341
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2 inhibitors: promise or peril?
Mengle-Gaw LJ; Schwartz BD
Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis.
Milas L
Am J Clin Oncol; 2003 Aug; 26(4):S66-9. PubMed ID: 12902859
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of selective COX-2 inhibitors.
Capone ML; Tacconelli S; Sciulli MG; Patrignani P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
[TBL] [Abstract][Full Text] [Related]
27. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
[TBL] [Abstract][Full Text] [Related]
28. [Current status of study on selective cyclooxygenase-2 inhibitors and evaluation of its application].
He W; Liu CF; Huang CQ
Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):184-6. PubMed ID: 12390825
[TBL] [Abstract][Full Text] [Related]
29. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks.
Moran EM
J Environ Pathol Toxicol Oncol; 2002; 21(2):193-201. PubMed ID: 12086406
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of action of antiinflammatory drugs.
Vane JR; Botting RM
Int J Tissue React; 1998; 20(1):3-15. PubMed ID: 9561441
[TBL] [Abstract][Full Text] [Related]
31. Approach to angiogenesis inhibition based on cyclooxygenase-2.
Masferrer J
Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
[TBL] [Abstract][Full Text] [Related]
32. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
[TBL] [Abstract][Full Text] [Related]
33. Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.
Lang S; Zeidler R
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):41-8. PubMed ID: 14552703
[TBL] [Abstract][Full Text] [Related]
34. Radioprotection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins.
Lee TK; Stupans I
J Pharm Pharmacol; 2002 Nov; 54(11):1435-45. PubMed ID: 12495545
[TBL] [Abstract][Full Text] [Related]
35. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
Reddy BS; Rao CV
J Environ Pathol Toxicol Oncol; 2002; 21(2):155-64. PubMed ID: 12086402
[TBL] [Abstract][Full Text] [Related]
36. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
37. Development of COX inhibitors in cancer prevention and therapy.
Umar A; Viner JL; Anderson WF; Hawk ET
Am J Clin Oncol; 2003 Aug; 26(4):S48-57. PubMed ID: 12902856
[TBL] [Abstract][Full Text] [Related]
38. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
Gerstenfeld LC; Thiede M; Seibert K; Mielke C; Phippard D; Svagr B; Cullinane D; Einhorn TA
J Orthop Res; 2003 Jul; 21(4):670-5. PubMed ID: 12798067
[TBL] [Abstract][Full Text] [Related]
39. Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Grover JK; Yadav S; Vats V; Joshi YK
Int J Colorectal Dis; 2003 Jul; 18(4):279-91. PubMed ID: 12774242
[TBL] [Abstract][Full Text] [Related]
40. Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Peek RM
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S50-6. PubMed ID: 15309515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
